XNAS · Healthcare · Biotechnology
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
FDA first-round review of preservative-free ketamine found no major chemistry deficiencies, a meaningful regulatory de-risking for this biotech. But Q2 was weak: **$1M** revenue and **$(0.44)** EPS both missed, underscoring heavy losses and execution risk.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-17 | Q2 2026 | -0.12 | -0.44 | -266.67% | $1.1M | ❌ Miss | -2.75% | +0.58% | — |
| 2026-05-15 | Q1 2026 | -0.10 | -0.04 | +60.00% | $1.1M | ✅ Beat | -0.93% | -1.83% | +24.39% |
| 2026-03-23 |
| Q4 2025 |
| -0.08 |
| 0.20 |
| +350.00% |
| $983,000 |
| ✅ Beat |
| +1.69% |
| +18.08% |
| +67.80% |
| 2025-11-17 | Q3 2025 | -0.05 | -0.27 | -440.00% | $242,000 | ❌ Miss | — | — | — |
| 2025-08-18 | Q2 2025 | -0.23 | -0.98 | -326.09% | $0 | ❌ Miss | +8.65% | -2.54% | +5.80% |
| 2025-03-17 | Q4 2024 | — | -0.77 | — | $0 | — | +7.32% | +0.98% | -5.85% |
| 2024-11-14 | Q3 2024 | -0.69 | -0.15 | +78.26% | $0 | ✅ Beat | +2.59% | +6.03% | +3.45% |
| 2024-08-14 | Q2 2024 | -0.58 | -0.75 | -29.31% | $0 | ❌ Miss | -6.45% | +2.15% | -7.53% |
Showing last 8 quarters.